Twin Lakes Capital Management’s Alterity Therapeutics ATHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$485K Hold
139,258
0.22% 57
2025
Q4
$429K Hold
139,258
0.19% 63
2025
Q3
$524K Buy
139,258
+133,333
+2,250% +$643K 0.24% 55
2025
Q2
$24.2K Hold
5,925
0.01% 163
2025
Q1
$20.4K Hold
5,925
0.01% 168
2024
Q4
$19.6K Hold
5,925
0.01% 180
2024
Q3
$7.78K Hold
5,925
0.01% 205
2024
Q2
$10.7K Hold
5,925
0.01% 199
2024
Q1
$12.3K Hold
5,925
0.01% 198
2023
Q4
$14.8K Hold
5,925
0.01% 188
2023
Q3
$14.7K Hold
5,925
0.01% 192
2023
Q2
$16.5K Hold
5,925
0.01% 186
2023
Q1
$16.4K Buy
+5,925
New +$20.2K 0.01% 185

Other funds holding ATHE

Twin Lakes Capital Management's ATHE Position: Q1 2026 in Review

Twin Lakes Capital Management held its Alterity Therapeutics (ATHE) position steady in Q1 2026 at 139,258 shares worth $485K. The position accounts for 0.22% of the portfolio, ranked #57.

Twin Lakes Capital Management first reported a position in ATHE in Q1 2023 and has held it in 13 quarters since. The position peaked at $524K in Q3 2025. 15 funds tracked by Wall St. Rank hold ATHE as of Q1 2026.

  • Twin Lakes Capital Management held 139,258 shares of Alterity Therapeutics worth $485K as of Q1 2026.
  • Twin Lakes Capital Management left its Alterity Therapeutics share count unchanged in Q1 2026.
  • Alterity Therapeutics made up 0.22% of Twin Lakes Capital Management's portfolio in Q1 2026, its #57 holding.
  • Twin Lakes Capital Management first reported a position in Alterity Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Twin Lakes Capital Management's Alterity Therapeutics position peaked at $524K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2026.

Based on Twin Lakes Capital Management's 13F filing for Q1 2026, filed 18 May 2026.